Adverse Effects of Anastrozole in Patients With DCIS

July 17, 2015
Adam M. Brufsky, MD, PhD

Adam M. Brufsky, MD, PhD, ​professor of medicine, University of Pittsburgh School of Medicine, associate director of clinical investigation, University of Pittsburgh Cancer Institute, discusses the adverse effects, as well as future treatments, of anastrozole in patients with ductal carcinoma In situ (DCIS).

Brufsky mentions that the two main adverse effects are arthralgia and bone loss. Severe arthralgia occurs in only 10% of patients, and it typically alleviates on its own. There are ways to prevent bone loss as well.

Brufsky believes it would be beneficial to define the subtypes of DCIS that need little to no treatment.

Adam M. Brufsky, MD, PhD, ​professor of medicine, University of Pittsburgh School of Medicine, associate director of clinical investigation, University of Pittsburgh Cancer Institute, discusses the adverse effects, as well as future treatments, of anastrozole in patients with ductal carcinoma In situ (DCIS).